The global Infectious Disease Diagnostics Market continues to expand at a strong pace, driven by rising infectious disease prevalence, accelerated technological innovation, and increasing investments in diagnostic infrastructure worldwide. Valued at US$24.96 billion in 2024, the market grew to US$26.58 billion in 2025 and is projected to reach US$42.20 billion by 2030, advancing at a robust CAGR of 9.7% from 2025 to 2030. This sustained growth underscores the critical need for accurate, rapid, and accessible diagnostic solutions across hospitals, clinics, laboratories, and point-of-care (POC) settings.

Infectious diseases—ranging from respiratory and gastrointestinal illnesses to vector-borne and emerging viral infections—continue to pose global health challenges. Early detection remains one of the most powerful tools to prevent outbreaks, control disease progression, and guide timely treatment decisions. As governments and healthcare systems increase their focus on preparedness and rapid response, diagnostic technologies are becoming central pillars of modern healthcare strategies.

Download PDF Brochure

Key Market Growth Drivers

1. Rising Global Disease Burden

The increasing incidence of infectious diseases such as influenza, tuberculosis, HIV, hepatitis, tropical diseases, and newly emerging pathogens continues to accelerate demand for advanced diagnostic tools. Urbanization, climate change, antimicrobial resistance (AMR), and global mobility further heighten the risk of outbreaks—driving the need for faster, more scalable diagnostic solutions.

2. Growing Demand for Early & Accurate Diagnosis

Healthcare providers and public health agencies rely heavily on sensitive and specific diagnostic methods to make informed clinical decisions. The demand for early detection is fueled by:

• The need to initiate targeted treatment quickly
• Efforts to prevent cross-infection
• Rising efforts to monitor antimicrobial resistance patterns
• Greater emphasis on personalized infectious disease care

Rapid diagnostic test (RDT) kits, molecular diagnostics, immunodiagnostics, and next-generation technologies are at the forefront of facilitating accurate clinical insights.

3. Government Support and Funding

Global governments, NGOs, and health agencies are significantly increasing investments in infectious disease surveillance, laboratory modernization, and emergency preparedness. Funding programs support:

• R&D in molecular and rapid diagnostics
• Expansion of laboratory capacity
• Universal testing and screening programs
• Development of decentralized and point-of-care testing

These initiatives continue to accelerate innovation, improve diagnostic access, and strengthen market growth.

Market Segmentation Analysis

1. By Product & Service

Segments:

• Reagents, kits, and consumables (Largest share in 2024)
• Instruments
• Software & services

The reagents, kits, and consumables segment dominates, owing to the high volume of items consumed during routine diagnostic testing. Unlike instruments, consumables require continuous replenishment, creating steady demand. Their broad availability, constant usage in clinical workflows, and essential role in delivering test accuracy bolster their prominence in the market.

2. By Sample Type

Segments:

• Blood, serum, and plasma (Largest share in 2024)
• Urine
• Other samples (swabs, sputum, saliva, CSF, etc.)

Blood, serum, and plasma remain the most frequently used sample types due to their high diagnostic value. These samples contain enriched concentrations of:

• Biomarkers
• Circulating nucleic acids (DNA/RNA)
• Proteins and antibodies
• Pathogen-specific antigens

This makes them ideal for diagnosing bacterial, viral, and parasitic infections, enabling clinicians to detect infection stages, monitor progression, and guide personalized treatment approaches.

3. By Geography

Regions covered:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America led the market in 2024, with the US as the dominant contributor. Several factors drive this dominance:

• Strong healthcare infrastructure
• Advanced laboratory networks
• High adoption of molecular and POC diagnostics
• Significant investments in infectious disease research
• Presence of major global diagnostic manufacturers

Emerging economies in the Asia Pacific region are expected to exhibit the fastest growth in the coming years due to rising healthcare spending, improving diagnostic access, and widespread infectious disease challenges.

Competitive Landscape: Key Market Players

The infectious disease diagnostics market is highly competitive, with global leaders offering extensive portfolios across molecular diagnostics, immunoassays, rapid tests, and POC platforms. Major players include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott (US)
• Danaher Corporation (US)
• bioMérieux (France)
• Thermo Fisher Scientific Inc. (US)
• Siemens Healthineers AG (Germany)
• Becton, Dickinson and Company (US)
• Hologic, Inc. (US)
• QIAGEN N.V. (Netherlands)
• Bio-Rad Laboratories, Inc. (US)

F. Hoffmann-La Roche Ltd. (Switzerland)

Roche remains a global leader supported by a vast distribution network across all major regions. The company uses a combination of direct and indirect sales channels to address market fluctuations and sustain global presence. Roche also strengthens its portfolio through strategic acquisitions and collaborations, focusing on molecular diagnostics and high-performance infectious disease testing platforms.

Danaher Corporation (US)

Danaher holds a strong market position due to its diversified diagnostic ecosystem and subsidiaries such as Cepheid and Beckman Coulter. Its global distribution capabilities, consistent technology integration, and active partnerships make it a significant player in molecular and immunodiagnostic testing. Danaher’s focus on innovation and inorganic growth strategies enables it to penetrate high-growth market segments effectively.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Conclusion

The infectious disease diagnostics market is undergoing transformative growth driven by rising disease prevalence, urgent demand for rapid testing, and significant advancements in molecular and immunodiagnostic technologies. As governments and healthcare organizations intensify their focus on surveillance and preparedness, the market is poised for rapid expansion through 2030.

With innovations in PCR, next-generation sequencing (NGS), rapid antigen/antibody testing, and fully automated platforms, the diagnostics landscape is evolving toward faster, more accurate, and decentralized testing solutions. As leading companies continue to invest in R&D, partnerships, and global accessibility, infectious disease diagnostics will remain a cornerstone of modern healthcare and public health infrastructure.